Roivant Sciences (87S) Q1 2026 Earnings Report

The call emphasized strong pipeline progress (potential DM launch, Phase III initiation in cutaneous sarcoidosis, multiple H2 2026 readouts), a sizable settlement cash inflow, active share buybacks, and continued R&D investment. Management was candid about clinical and regulatory risks (placebo variability, translation risk for PH‑ILD, randomized withdrawal uncertainty in D2T RA), limited early commercial visibility, JAK class safety perceptions, and contingent litigation outcomes. On balance, the positives (multiple near-term catalysts, strengthened balance sheet, active capital return, and robust R&D investment) outweigh the enumerated risks, which are largely development and execution uncertainties the company is actively managing.

Management's guidance was a "slow and steady" commercial approach with limited early launch metrics to be disclosed: brepocitinib has priority review/PDUFA this quarter and is expected to launch by end‑September, while a busy 2H26 is planned with topline readouts for NIU, mosli (PH‑ILD) and CLE, D2T‑RA updates including the Part‑2 randomized‑withdrawal data and an FDA discussion, and ongoing LPP enrollment; mosli is expected to show a clear PVR signal (study not powered for 6‑minute walk). The cutaneous sarcoidosis Phase III is now enrolling (16‑week, 140 patients across ~70 sites, 3:2 randomization, 45 mg with a mandatory steroid taper weeks 2–8) with topline in 2028. Financially, Q1 R&D expense was about $200M, non‑GAAP adjusted G&A just under $100M (GAAP G&A $166M), cash was just under $4B (pre‑receipt of proceeds from the Moderna settlement), Roivant reported the ~$950M Moderna settlement (≈$770M to Genevant, remainder to Arbutus), expects to receive roughly $772M, executed ~ $200M of share repurchases in the quarter (prior buybacks totaled ~$1.5B at ~ $10/share; recent repurchases averaged in the high‑$20s), and noted potential additional legal upside (~$1.3B from the 1498 appellate) plus three international suits filed; by end‑2028 the company is targeting 3+ commercial launches, 9+ pivotal readouts and 4+ NDA/BLA filings.